JP2025511161A5 - - Google Patents
Info
- Publication number
- JP2025511161A5 JP2025511161A5 JP2024557983A JP2024557983A JP2025511161A5 JP 2025511161 A5 JP2025511161 A5 JP 2025511161A5 JP 2024557983 A JP2024557983 A JP 2024557983A JP 2024557983 A JP2024557983 A JP 2024557983A JP 2025511161 A5 JP2025511161 A5 JP 2025511161A5
- Authority
- JP
- Japan
- Prior art keywords
- groups
- group
- atoms
- substituted
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22305439 | 2022-04-04 | ||
| EP22305439.6 | 2022-04-04 | ||
| PCT/EP2023/058693 WO2023194310A1 (en) | 2022-04-04 | 2023-04-03 | Therapeutic combination of kras g12c inhibitor and tead inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025511161A JP2025511161A (ja) | 2025-04-15 |
| JP2025511161A5 true JP2025511161A5 (cg-RX-API-DMAC10.html) | 2026-04-10 |
Family
ID=81326107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024557983A Pending JP2025511161A (ja) | 2022-04-04 | 2023-04-03 | Ｋｒａｓ ｇ１２ｃ阻害剤及びｔｅａｄ阻害剤の治療的組合せ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250295664A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4504203A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025511161A (cg-RX-API-DMAC10.html) |
| CN (1) | CN118973584A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023194310A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020020307A2 (pt) | 2018-04-04 | 2021-01-12 | Arvinas Operations, Inc. | Moduladores de proteólise e métodos de uso associados |
| PE20260006A1 (es) | 2023-01-26 | 2026-01-06 | Arvinas Operations Inc | Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos |
| US12662707B2 (en) | 2024-01-24 | 2026-06-23 | The Trustees Of Columbia University In The City Of New York | MYC amplification drives resistance to pan-RAS inhibitors in pancreatic cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2863873T3 (es) | 2016-05-18 | 2021-10-11 | Mirati Therapeutics Inc | Inhibidores de KRAS G12C |
| CR20190338A (es) | 2016-12-22 | 2019-09-09 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso |
| UA127968C2 (uk) | 2017-05-22 | 2024-02-28 | Емджен Інк. | Інгібітори g12c kras і способи їх застосування |
| CA3082579A1 (en) | 2017-11-15 | 2019-05-23 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| MX2020010836A (es) | 2018-05-04 | 2021-01-08 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso. |
| AU2019338207B2 (en) * | 2018-09-10 | 2025-01-02 | Mirati Therapeutics, Inc. | Combination therapies |
| JP7377679B2 (ja) * | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| EP4065230A1 (en) * | 2019-11-27 | 2022-10-05 | Genentech, Inc. | Therapeutic compounds |
| WO2021204823A1 (en) | 2020-04-07 | 2021-10-14 | Sanofi | (1 h-indol-5-yl)acrylamide derivatives as inhibitors of tead proteins and the hippo-yap1/taz signaling cascade for the treatment of cancer |
| US11787775B2 (en) * | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
| CN116057042B (zh) | 2020-07-30 | 2024-10-18 | 赛诺菲 | 丙烯酰胺取代的茚满化合物及其治疗用途 |
-
2023
- 2023-04-03 EP EP23713397.0A patent/EP4504203A1/en active Pending
- 2023-04-03 US US18/852,884 patent/US20250295664A1/en active Pending
- 2023-04-03 WO PCT/EP2023/058693 patent/WO2023194310A1/en not_active Ceased
- 2023-04-03 CN CN202380032305.8A patent/CN118973584A/zh active Pending
- 2023-04-03 JP JP2024557983A patent/JP2025511161A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022201082B2 (en) | Benzimidazole compounds as c-Kit inhibitors | |
| JP2023505258A5 (cg-RX-API-DMAC10.html) | ||
| JP2022542396A5 (cg-RX-API-DMAC10.html) | ||
| JP6517790B2 (ja) | ４−アザインドール誘導体 | |
| IL279800B1 (en) | Selective allosteric inhibitors of epidermal growth factor receptor mutants, pharmaceutical preparations containing them and their use | |
| ES2638850T3 (es) | Compuestos de azabenzimidazol como inhibidores de las isoenzimas de la PDE4 para el tratamiento de trastornos del SNC y otros trastornos | |
| RU2015107831A (ru) | Новые соединения пирролопиримидина в качестве ингибиторов протеинкиназ | |
| JP2022552324A5 (cg-RX-API-DMAC10.html) | ||
| JP2011510995A5 (cg-RX-API-DMAC10.html) | ||
| JP2020503299A5 (cg-RX-API-DMAC10.html) | ||
| CA2651363A1 (en) | Triazolopyrazine derivatives useful as anti-cancer agents | |
| JP2016172739A5 (cg-RX-API-DMAC10.html) | ||
| JP2013523710A5 (cg-RX-API-DMAC10.html) | ||
| KR20170069199A (ko) | 섬유 아세포 성장 인자 수용체 키나아제 억제제인 인다졸계 화합물 및 이의 제조와 응용 | |
| WO2016065226A1 (en) | Indole carboxamides compounds useful as kinase inhobitors | |
| JP2018529770A (ja) | Ｊａｋを阻害するための化合物及び方法 | |
| RU2018134981A (ru) | Конъюгаты, содержащие ингибиторы RIPK2 | |
| EA024162B1 (ru) | Производные хинолина в качестве ингибиторов киназы | |
| JP2011507854A5 (cg-RX-API-DMAC10.html) | ||
| CN114174303A (zh) | 作为sting激动剂的大环化合物及其方法和用途 | |
| TW202313048A (zh) | 組合療法 | |
| JP2022546208A (ja) | 置換尿素ジヒドロオロト酸デヒドロゲナーゼ阻害剤 | |
| KR20220097439A (ko) | 암, 자가면역, 및 염증성 질환의 치료를 위한 다이하이드로오로테이트 데하이드로게나제(dhodh) 억제제로서의 플루오르화 퀴놀론, 퀴녹살린, 및 벤조[b][1,4] 옥사진 유도체 | |
| JP2010535204A5 (cg-RX-API-DMAC10.html) | ||
| JP2010515688A5 (cg-RX-API-DMAC10.html) |